Expedited Investigational New Drug Pilot Program; Request for Information
The Food and Drug Administration (FDA or the Agency) is opening a public docket to solicit input and comments on a proposal to establish a pilot program, the Expedited Investigational New Drug (IND) pilot program, to shorten the time it takes from drug identification to first-in-human (FIH) study, while protecting clinical trial participants. FDA is requesting information on the potential pilot program which would establish a network of qualified research institutions, such as academic medical centers (AMCs), healthcare networks (HNs), contract research organizations (CROs), regulatory advisors, and/or other research or third-party review organizations (collectively called Qualified Research Institutions, or "QRIs"), who would partner with sponsors to develop and review protocols for FIH clinical trials intended for a IND submission to FDA. Information provided through this public docket will help the Agency refine our approach and consider other opportunities to accelerate time to FIH clinical trials.
Open the source record- Tags
- health IT, Notice, Health and Human Services Department, Food and Drug Administration
- Related exam domains
- CISSP 4: Communication and Network Security; CISM 2: Information Security Risk Management; CISM 3: Information Security Program
- Source record id
- 2026-12621
- First seen by InfoSec Signals
- 9/23/2026
Exam domain labels come from a keyword heuristic and are study hints, not an official mapping. The summary is the publisher's own text, shortened; the linked record is authoritative.